Document:

exv10w40

 

Exhibit 10.40

Employment Agreement

     This employment agreement (“Agreement”), made and entered into this 20st day of
November 2006, by and between CytoCore, Inc., with its principal place of business at 414 North
Orleans Court, Suite 502 in Chicago, Illinois 60610 (the “Company”) and Robert McCullough Jr., 227
South Ridgewood, Kentfield, CA 94904 ( “McCullough”).

Background

     McCullough provides a variety of financial and business services as part of his duties as
Chief Financial Officer for CytoCore, and is ready, willing, and able to provide such assistance
to the Company on the terms and conditions set forth herein.

     The Company is in the process of developing a series of medical devices, drug delivery
Systems, and other cervical and uterine cancer related medical Systems. In pursuit of its business
strategy the Company desires to retain the services of McCullough under the terms and conditions
set forth herein.

     NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is
hereby acknowledged, the Company and McCullough agree as follows:

	 	1.	 	Engagement and Scope of Services.
	 
	 	1.1	 	Company hereby retains McCullough and McCullough agrees to provide to the
Company the employment services which are more fully described below:
	 
	 	 	 	Employment duties will involve but are not limited to interaction with the Company’s
Chief Executive Officer, Medical Advisory Board, other Officers, or consultants
related to or regarding the Company’s business plans, operations, commercialization
of medical devices, and other business matters that fall within McCullough’s area of
expertise. McCullough will report directly to the Board of Directors and the Audit
Committee comprised of members of the Board of Directors
	 
	 	 	 	McCullough will be responsible for the financial accounting and reporting of the
state of the Company’s financial operations and condition in accordance with rules
and regulations promulgated by regulatory authorities. McCullough has the authority
to hire necessary personnel and consultants to achieve this objective. and discharge
same. McCullough will be responsible for generating financial projections and will
have direct access to all personnel and consultants employed by the Company in order
to obtain necessary information for such projections. Company will provide direct
access to all computers and computer generated information required for financial
statement preparation. Company will reimburse McCullough. for attending seminars that
McCullough feels are essential to perform the duties listed above

l of 6

 

 

	 	 	 	McCullough shall perform such assignments made by the Board of Directors C
	 
	 	1.2	 	This Agreement is a non-exclusive agreement. McCullough is free to provide similar or
different services to any other company or organization desiring his services, provided,
however, such services will not interfere with the performance of his duties hereunder and
his services are not provided to any competitors of CytoCore.
	 
	 	1.3	 	McCullough shall perform such services from whatever location he elects, but will be in
Chicago at such times as are necessary for the performance of his duties.

     Term of Agreement.

	 	2.1	 	This Agreement shall supersede the Agreement that is in place between CytoCore and
McCullough dated as of April 1, 2006 that has a twelve (12) month term. This Agreement shall
be for a period of twenty four (24) months from December 1, 2006, and shall terminate twenty
four (24) months from December 1, 2006 following written notice by either party to the other
at least thirty (30) days prior to the expiration date.

2.2 This Agreement is subject to termination in the event of a material breach of any term hereof
and the breaching party’s failure to cure such material breach to the on- breaching party’s
reasonable satisfaction within ten (10) business days of written notice.

	 	1.3	 	Within ten (10) business days of termination of this Agreement, McCullough shall submit to
the Company an itemized invoice for any remaining unpaid fees or reimbursable expenses then
due and owing under this Agreement. Company, upon receipt and payment of such final invoice
shall thereafter have no further obligation for payment under this Agreement. Upon the
termination of this Agreement and payment in full of all monies due and owed from Company to
McCullough pursuant to this Agreement, McCullough shall promptly return to Company all copies
of any Company data, information, documents, or other materials of any sort stored in any
form whatsoever, including all materials incorporating any of the Company’s Confidential
Information.
	 
	 	2.	 	Compensation, Expenses, and Payments.
	 
	 	3.1	 	The Company shall pay McCullough-Ten Thousand Dollars ($10,000.00) for each month he provides
services to the Company. At such time as the Company has raised additional funding equal to
Five Million Dollars ($5,000,000), the Company’s payment to McCullough will increase to
Fifteen Thousand Dollars ($15,000) per month for the balance of the term of this Agreement.

2 of 6

 

 

	 	3.2	 	McCullough will also receive various grants of warrants to purchase CytoCore stock. The
warrant grants and their associated performance triggers are listed in Addendum A.
	 
	 	3.3	 	The Company shall reimburse McCullough for his out-of-pocket expenses related to the
performance of his duties hereunder pursuant to the Company’s usnal expense reimbursement
procedures. McCullough acknowledges that he will comply with said procedures. Further,
McCullough agrees to comply with the Company’s Code of Ethics and Business Conduct for
Officers, Directors and Employees of CytoCore, Inc.
	 
	 	3.4	 	Company agrees to provide health insurance for McCullough and his children during the term
of this Agreement.
	 
	 	3.	 	Proprietary Information.
	 
	 	3.1	 	McCullough acknowledges that in order to perform his services hereunder, it may be necessary
for the Company to disclose certain confidential technical, medical, or commercial
information (“Confidential Information”) to him. McCullough agrees that he shall not
disclose, transfer use, copy. or allow access to any such Confidential Information to any
third parties without the Company’s express written approval except those who have a need to
know such Information and are obligated to maintain the confidentiality of such Information.
The foregoing shall not apply to that information which was already known to McCullough as of
April 1, 2006 before disclosure, is publicly disseminated through no fault of McCullough or
the Company, is rightfully received from a third party, or is required to be disclosed
pursuant to court order. This provision shall survive the termination or expiration of this
Agreement and continue in effect for a period of three (3) years.
	 
	 	4.	 	Warranty and Exclusion of Warranty.
	 
	 	4.1	 	McCullough warrants that his services will be of professional quality and performed in
accordance with the terms hereof.
	 
	 	4.2	 	The foregoing warranty is in lieu of all other warranties, conditions, or representations,
express or otherwise, including without limitation any implied warranties of merchantability
or fitness of use for a particular purpose.
	 
	 	5.	 	Termination.
	 
	 	5.1	 	This Agreement may be terminated by either party to this Agreement upon thirty (30) days
prior written notice to the other party. This termination may be without cause. If this
Agreement is terminated by the Company without cause, the Company shall pay McCullough on a
monthly basis the balance of what he is entitled to in Section 3.1 above. for the duration of
the 24 month employment

3 of 6

 

 

	 	 	 	term and health insurance for him and his children during the duration of this
agreement.
	 
	 	6.	 	No Interference.
	 
	 	6.1	 	For the period commencing on the date hereof and ending on the date twenty
four (24) months after the date this Agreement is terminated, the Contractor agrees he
shall not:

	 	(a)	 	Take any action which would:

	 	(i)	 	Interfere with the contractual relationships of
the Company or any affiliate of the Company, customers, suppliers, other
consultants, employees, or others which relate to the business of the
Company or any affiliate of the Company; or
	 
	 	(ii)	 	Induce any employee, consultant, or representative
of the Company or any affiliate of the Company not to become or not to
continue as an employee, McCullough, or representative of the Company or
affiliate of the Company.
	 
	 	(iii)	 	Disparage, orally or in writing, or diminish the
reputation of the Company or any entity affiliated with the Company.

     7.2 McCullough recognizes that irreparable damage will result to the Company and its business
if McCullough fails to or refuses to perform his obligations referred to in Sections 4 and 7 of
this Agreement. Accordingly, in addition to any remedies and damages available, the Company shall
be entitled to request injunc5tive relief and McCullough may be specifically compelled to perform
his obligations hereunder.

	 	7.	 	General.
	 
	 	7.1	 	This Agreement is made and entered into, and is to be at least partially
performed, in Cook County, Illinois. It shall be interpreted, construed and enforced
by, and its construction and performance shall be governed by, the laws of the State
of Illinois applicable to written agreements made and to be performed entirely within
Illinois without regard to principles of conflicts of laws, except to the extent that
Federal law may apply.
	 
	 	7.2	 	All notices required to be given hereunder shall be in writing and addressed to
the respective parties set forth herein, unless another address shall have been
previously designated in writing to the other party. Notice shall be deemed sent

4 of 6

 

 

	 	 	 	and effective when delivered by hand delivery, via U.S. Mail,
Certified, with return receipt requested, or via regular U.S. Mail
and confirmed facsimile delivery.
	 
	 	7.3	 	This Employment Agreement constitutes the complete and entire
Agreement . between McCullough and the Company with respect to the subject
matter hereof. This Agreement supersedes all prior agreements, contracts,
representations, proposals, discussions, and communications, whether oral or
in writing, relating hereto. This Agreement may be modified only in writing
signed by both McCullough and a duly authorized representative of the
Company.
	 
	 	7.4	 	This Agreement may be executed in counterparts or with
facsimile signatures, all of which shall constitute an original.
	 
	 	7.5	 	In the event any portion of this Agreement is deemed to be
invalid or unenforceable, that portion will be deemed to be omitted and the
remainder of this Release will remain in full force and effect.
Signatures

	 	 	 
	The Company
	 	 
	 Cytocore, Inc.

	 	Robert McCullough, Jr.
	 
	 	 
	/s/ David Weissberg

	 	/s/ Robert McCullough, Jr.
	 

	 	 
	By: David Weissberg

	 	By: Robert McCullough, Jr.
	Title: CEO

	 	Title:
	Date: November 20, 2006

	 	Date:

5 of 6

 

 

Addendum A.

1. Performance Milestones:

McCullough will be granted warrants based on the following performance milestones.

     A.) 150,000 warrants upon product completion of FDA product trials and receipt of all
necessary FDA approvals.

     B.) 250,000 warrants when the Company raises 5 million in equity at a price above $.22/Share

     C.) 100,000 warrants when the Company signs a distribution agreement for the E2
collecter.

     D.) 250,000 warrants when the Company’s stock price trades above $.30 for 45 out of 60 trading
days.

     E.) 250,000 warrants when the Company’s stock price trades above $.50 for 45 out of 60 trading
days

     F.) 500,000 warrants when the Company’s stock price trades above $1.00 for 45 out of 60
trading days.

All the warrants listed in categories 1. (A) through (F) will have an exercise price at a 33%
discount to the average closing price of the Company’s stock price during the prior forty five days
before the target as described above is reached.

2. Revenue Milestones:

     McCullough will be granted 500,000 warrants when the company’s revenue reaches $20
million and 500,000 warrants when the Company’s revenue reaches $50 million. Exercise price will be
at a 33% discount to the average trading price of the Company’s stock for a period of 45 days prior
to the attainment of the revenue milestones.

3. Acquisition of Company:

     A.) McCullough will receive 1.25 million warrants to purchase the Company’s stock at $.25 if
the company is acquired for more than $1.00.

     B.) McCullough will receive 1.75 million warrants to purchase the Company’s stock at $.50 if
the company is acquired for more than $2.00

     C.) McCullough will receive 2.5 million warrants each to purchase the Company’s stock at $.75
if the company is acquired for more than $3.00.

The Company agrees to facilitate a cash less exercise of the warrants.

6 of 6exv10w41

 

Exhibit 10.41

Consulting Services Agreement

     This consulting services agreement (“Agreement”), made and entered into on November 20, 2006,
and effective as of the lst day of December 2006, by and between CytoCore, Inc. with
its principal place of business at 414 North Orleans Court, Suite 502 in Chicago, Illinois 60610
(the “Company”) and Future Wave Management, with its mailing address of P.O. Box 1086, Del Mar,
California 92914-1086 (the “Consultant”).

Background

     The Consultant provides a variety of financial and business consulting services as part of
his regular business with Future Wave Management, and is ready, willing, and able to provide such
consulting assistance to the Company on the terms and conditions set forth herein.

     The Company is in the process of developing a series of medical devices, drug delivery
systems, and other cervical and uterine cancer related medical systems. In pursuit of its business
strategy the Company desires to retain the services of the Consultant under the terms and
conditions set forth herein.

     NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is
hereby acknowledged, the Company and the Consultant agree as follows:

	 	1.	 	Engagement and Scope of Services.
	 
	 	1.1	 	Company hereby retains consultant and Consultant agrees to provide to the
Company the consulting services which are more fully described below:
	 
	 	 	 	Consulting with the Company’s Chief Executive Officer, Chief Financial Officer,
Medical Advisory Board, other Officers, or other consultants related to or regarding
certain business plans, operations, commercialization of medical devices or theories,
and other business matters that fall within the Consultant’s area of expertise.
	 
	 	 	 	Consultant will have no authority or responsibility with regard to execution of any
contract on behalf of the Company. Consultant is not an employee or officer of the
Company.
	 
	 	 	 	Consultant will provide progress reports from time to time to the Company’s Chief
Executive Officer. Consultant agrees to provide any such report in writing if so
requested by the Company’s Chief Executive Officer.
	 
	 	1.2	 	This Agreement is a non-exclusive agreement. The Consultant is free to
provide similar or different services to any other company or organization desiring his
services, provided that the Consultant is able to provide the Company the services

 1 of 6

 

	 	 	 	here agreed upon from month to month. The Company is also free to acquire simitar services
from any other party should it desire to do so.
	 
	 	2.	 	Term of Agreement.
	 
	 	2.1	 	This Agreement shall supersede the Agreement that is in place between CytoCore and Future
Wave Management, Inc. beginning on April 1, 2006 that has a twelve (12) month term. The term
of this Agreement shall be for a period of twenty four (24) months from the date of
execution, and shall terminate twenty four (24) months from signing date following written
notice by one r party to the other at least thirty (30) days prior to the expiration date.
	 
	 	2.2	 	This Agreement is subject to termination in the event of a material breach of any term hereof
and the breaching party’s failure to cure such material breach to the non-breaching party’s
reasonable satisfaction within ten (10) business days of written notice.
	 
	 	2.3	 	Within ten (10) business days of termination of this Agreement, Consultant shall submit to
the Company an itemized invoice for any remaining unpaid fees or reimbursable expenses then
due and owing under this Agreement. Company, upon receipt and payment of such final invoice
shall thereafter have no further obligation for payment under this Agreement. Upon the
termination of this Agreement other than the surviving obligation, if any, under Section 6.1
below and payment in full of all monies due and owed from Company to Consultant pursuant to
this Agreement, Consultant shall promptly return to Company all copies of any Company data,
information, documents, or other materials of any sort stored in any form whatsoever,
including all materials incorporating any of the Company’s proprietary information.
	 
	 	3.	 	Fees. Expenses, and Payments.
	 
	 	3.1	 	The Company shall pay Consultant a fee of Ten Thousand Dollars ($10,000.00) for each month
it provides services to the Company. At such time as the Company has raised additional
funding of Five Million Dollars ($5,000,000), the payment to Consultant shall be increased to
Fifteen Thousand Dollars ($15,000.00) per month for the balance of the term of this
Agreement.
	 
	 	3.2	 	EMB will also receive various grants of warrants to purchase CytoCore stock.
The warrant grants and their associated performance triggers are listed in Addendum A
attached hereto and made a part of. this Agreement.
	 
	 	3.3	 	The Company shall reimburse the Consultant for its out-of-pocket expenses
related to this Agreement pursuant to the Company’s usual expense
reimbursement procedures. The Consultant acknowledges that he will comply
with said procedures. Further, the Consultant agrees to comply with the
Company’s Code of Ethics and Business Conduct for Officers, Directors and

 2 of 6

 

	 	 	 	Employees of CytoCore, Inc. Finally, Consultant agrees that he is an independent contractor
solely responsible for the determination and payment, if any, of all applicable federal,
state, and local taxes related to this Agreement.
	 
	 	4.	 	Proprietary Information.
	 
	 	4.1	 	The Consultant acknowledges that in order to perform the services called for in this
Agreement, it may be necessary for the Company to disclose to Consultant certain confidential
technical, medical, or commercial information (“Confidential Information”). The Consultant
agrees that without the Company’s express written approval Consultant and its senior
employees shall, not, disclose, transfer, use, copy or allow access to any such Confidential
Information to any third parties, except those who have a need to know such Information and
are obligated to maintain the confidentiality of such Information. The foregoing shall not
apply to that Information which was already known to the Consultant before disclosure, is
publicly disseminated through no fault of either the Consultant, is rightfully received from
a third party or is required to be disclosed pursuant to court order. This provision shall
survive the termination of this Agreement and continue in effect for a period of three (3)
years.
	 
	 	5.	 	Warranty and Exclusion of Warranty.
	 
	 	5.1	 	The Consultant warrants that (i) its services will be of professional quality and performed
in accordance with the terms hereof and (ii) Consultant is under no obligation, the
enforcement of which would prevent it from performing the services required hereunder.
	 
	 	5.2	 	The foregoing warranties are in lieu of all other warranties, conditions, or
representations, express or otherwise, including without limitation any implied warranties
of merchantability or fitness of use for a particular purpose.
	 
	 	6.	 	Termination.
	 
	 	6.1	 	This Agreement may be terminated by either party to this Agreement upon thirty (30) days
prior written notice to the other party. This termination may be without cause. If this
Agreement is terminated without cause by the Company, the Company will be obligated to pay
the Consultant the balance of the fees’ and expenses due for the remainder of the Agreement.
	 
	 	7.	 	No Interference.
	 
	 	7.1	 	For the period commencing on the date hereof and ending on the date twenty four (24) months
after the date this Agreement is terminated, the Contractor agrees he shall not:

	 	(a)	 	take any action which would:

 3 of 6

 

	 	(i)	 	interfere with the contractual relationships of the Company or any
affiliate of the Company, customers, suppliers, other consultants,
employees, or others which relate to the business of the Company or any
affiliate of the Company; or
	 
	 	(ii)	 	induce any employee, consultant, or representative of the
Company or any affiliate of the Company not to become or not to continue as an
employee, consultant, or representative of the Company or affiliate of the
Company.

	 	(b)	 	make remarks or take any other action which would tend to disparage or diminish
the reputation of the Company or any entity affiliated with the Company.

	 	8.	 	General.
	 
	 	8.1	 	This Agreement is made and entered into, and is to be at least partially performed, in Cook
County, Illinois. It shall be interpreted, construed and enforced by, and its construction
and performance shall be governed by, the laws of the State of Illinois applicable to written
agreements made and to be performed entirely within Illinois without regard to principles of
conflicts of laws, except to the extent that Federal law may apply.
	 
	 	8.2	 	All notices required to be given hereunder shall be in writing and addressed to the
respective parties set forth herein, unless another address shall have been previously
designated in writing to the other party. Notice shall be deemed sent and effective when
delivered by hand delivery, via U.S. Mail, Certified, with return receipt requested, or via
regular U.S. Mail and confirmed facsimile delivery.
	 
	 	8.3	 	This Agreement constitutes the complete and entire Agreement between the Consultant and the
Company with respect to the subject matter hereof. This Agreement supersedes all prior
agreements, contracts, representations, proposals, discussions, and communications, whether
oral or in writing, relating hereto. This Agreement may be modified only in writing signed by
both the Consultant and a duly authorized representative of the Company.
	 
	 	8.4	 	This Agreement may be executed in counterparts or with facsimile signatures, all of which
shall constitute an original.

 4 of 6

 

	 	8.5	 	In the event any portion of this Agreement is deemed to be invalid or
unenforceable, that portion will be deemed to be omitted and the remainder of this
Release will remain in full force and effect.
	 
	 	9.	 	Signatures

	 	 	 	 	 	 	 
	The Company

	 	 	 	The Consultant	 	 
	 
	 	 	 	 	 	 
	CytoCore, Inc.

	 	 	 	FUTURE WAVE MANAGEMENT	 	 
	 
	 	 	 	 	 	 
	/s/ Robert McCullough
	 	 	 	 	 	 
	 

By: Robert McCullough

	 	 
	 	 

By:
	 	 
	Title: Chief Financial Officer

	 	 	 	Title:	 	 
	Date: November 20, 2006

	 	 	 	Date:	 	 

 5 of 6

 

Addendum A.

1. Performance Milestones:

Future Wave Management, Inc. will be granted warrants based on the following performance
milestones.

     A ) 150,000 warrants upon product completion of FDA product trials and receipt of all
necessary FDA approvals.

     B.) 250,000 warrants when the company raises 5 million in equity at a price above
$.22/share.

     C.) 100,000 warrants when the company signs a distribution agreement for the E2
collector.

     D.) 250,000 warrants when the company’s stock price trades above $.30 for 45 out of 60 trading
days.

     E.) 250,000 warrants when the company’s stock price trades above $.50 for 45 out of 60 trading
days

     F.) 500,000 warrants when the company’s stock price trades above $1.00 for 45 out of 60
trading days.

All the warrants listed in categories 1. (A) through (F) will have an exercise price at a 33%
discount to the average closing price of the company’s stock price during the prior forty five days
before the target as described above is reached.

2. Revenue Milestones:

     A.) Future Wave Management, Inc. will be granted 500,000 warrants when the company’s revenue
reaches $20 million and 500,000 warrants when the company’s revenue reaches $50 million. Exercise
price will be at a 33% discount to the average trading price of the company’s stock for a period of
45 days prior to the attainment of the revenue milestones.

3. Acquisition of Company:

     A.) Future Wave Management, Inc. will receive 1.25 million warrants to purchase the company’s
stock at $.25 if the company is acquired for more than $1.00.

     B.) Future Wave Management, Inc. will receive 1.75 million warrants to purchase the company’s
stock at $.50 if the company is acquired for more than $2.00

     C.) Future Wave Management, Inc. will receive 2.5 million warrants each to purchase the
company’s stock at $.75 if the company is acquired for more than $3,00.

 6 of 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00121-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00121-of-00352.parquet"}]]